Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
Study Details
Study Description
Brief Summary
A Phase III Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on Myelosuppressive Therapy for Non Myeloid Malignancies.
Adult patients (18 years of age or older) diagnosed as having any malignancy (except myeloid malignancy, ECOG status of 0-2 and having a history of experiencing neutropenia (absolute neutrophil count < 1000/mm3) in a previous chemotherapy cycle and have one more cycle of chemotherapy on the same drugs would be recruited into the study.
Treatment will be initiated not earlier than 24 hours after the administration of cytotoxic chemotherapy in both groups.
Group 1: Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha)
-
Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier Group 2: Neupogen (rhG-CSF)
-
Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier Primary End Point would be to evaluate the percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C or developing a temperature of > 38°C twice in a 12-hour period and absolute neutrophil count < 0.5 x 109/L on the same day of the fever or the day after)in the two treatment groups.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier |
Biological: Recombinant Human GCSF (Shantha Biotechnics Limited)
Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
|
| Active Comparator: 2 Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier |
Biological: Neupogen
Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
|
Outcome Measures
Primary Outcome Measures
- Percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C or developing a temperature of > 38°C twice in a 12-hour period and absolute neutrophil count < 0.5 x 10e9/L on the same day of the fever or the day after. [End of study]
Secondary Outcome Measures
- Percentage of patients developing adverse events and/ or changes in laboratory values. [End of study]
- Incidence of neutropenia defined as absolute neutrophil count < 0.5 x 10e9/L not associated with fever [End of study]
- Incidence of need for IV anti-infectives and days of admission, as a result of neutropenia [End of study]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients of either sex aged 18 yrs or more
-
Patients diagnosed having any malignancy (except myeloid malignancies and myelodysplastic syndromes) receiving standard combination chemotherapy.
-
Patients experiencing neutropenia (absolute neutrophil count < 1000/mm3) in a previous chemotherapy cycle and have one more cycle of chemotherapy on the same drugs.
-
Patients should have performance status of 0-2 ECOG (European Cooperative Oncology group).
Exclusion Criteria:
-
Patients unwilling to give informed consent or unable to follow study procedures
-
Patients requiring autologous or allogenic stem cell transplantation.
-
Patients having active infection
-
Patients who have taken antibiotics or colony stimulation factor within the previous 10 days
-
Patients who have clinically significant uncontrolled medical illness except malignancy
-
Patients having renal impairment (serum creatinine > 1.5 times the upper normal limit) and abnormal liver function (bilirubin > 5 times the upper limit of normal)
-
Pregnant or lactating women
-
Patients who have involvement of bone marrow
-
Patients receiving simultaneous radiotherapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Indo American Cancer Institute and Research Centre | Hyderabad | Andhra Pradesh | India | 500034 |
| 2 | Nizam's Institute of Medical Sciences | Hyderabad | Andhra Pradesh | India | 500034 |
| 3 | Vedanta Institute of Medical Sciences | Ahmedabad | Gujrat | India | 380009 |
| 4 | Lakeshore Hospital and Research Center | Cochin | Kerala | India | 682404 |
| 5 | Regional Cancer Centre | Trivandrum | Kerala | India | 695011 |
| 6 | Seth Ramdas Shah Memorial Hospital | Pune | Maharashtra | India | 411016 |
| 7 | SMS Medical College and Hospital | Jaipur | Rajasthan | India | 302004 |
Sponsors and Collaborators
- Shantha Biotechnics Limited
Investigators
- Study Director: Raman Rao, MD, Shantha Biotechnics Limited, Hyderabad, India
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SBL/GCSF/N/2007/0100